Is hormone replacement therapy (HRT) following risk-reducing salpingo-oophorectomy (RRSO) in BRCA1 (B1)- and BRCA2 (B2)-mutation carriers associated with an increased risk of breast cancer?
| Autor: | Claudine Isaacs, D G R Evans, Timothy R. Rebbeck, Christian F. Singer, Gail E. Tomlinson, Tara M. Friebel, Wendy S. Rubinstein, Susan M. Domchek, Patricia A. Ganz, Fergus J. Couch, Nadine Tung, Judy Garber, Susan L. Neuhausen, M. B. Daly, Rosalind A. Eeles, Henry T. Lynch, Ellen T. Matloff, J. N. Weitzel, Gabriella Pichert, O. I. Olopade |
|---|---|
| Rok vydání: | 2011 |
| Předmět: | |
| Zdroj: | Journal of Clinical Oncology. 29:1501-1501 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2011.29.15_suppl.1501 |
| Popis: | 1501 Background: Women with B1 and B2 mutation are at increased risk of breast and ovarian cancer, which is significantly reduced by RRSO. The reduction in breast cancer risk may be greatest prior to age 40; however, such early menopause can lead to significant menopausal symptoms and other health problems. Two small prior studies have suggested that HRT following RRSO does not increase the risk of breast cancer, but further data are needed. Methods: From the PROSE consortium, 1,299 B1 (n= 795) and B2 (n=504) mutation carriers who underwent RRSO following study ascertainment and in whom HRT status was known were followed prospectively. Data were collected on HRT use and subsequent breast cancer diagnosis. Results: In both B1 and B2 mutation carriers with ever use of HRT following RRSO, no increased risk of breast cancer was observed compared to those with no RRSO. In B1 carriers, HRT use both with (HR 0.52) and without (HR 0.29) RRSO was associated with a decreased risk of breast cancer. No increased risk... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|